{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:10:05Z","timestamp":1778721005441,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jns.2026.125916","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:48:45Z","timestamp":1776610125000},"page":"125916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association between statin use and survival in patients with ALS: A propensity score-matched analysis"],"prefix":"10.1016","volume":"486","author":[{"given":"Pedro","family":"Saldanha-Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manav V.","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhruv","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denizart","family":"Santos-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ario","family":"Mirian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorne","family":"Zinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agessandro","family":"Abrahao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2026.125916_bb0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s13670-015-0127-8","article-title":"Amyotrophic lateral sclerosis: an aging-related disease","volume":"4","author":"Logroscino","year":"2015","journal-title":"Curr. Geriatr. Rep."},{"issue":"1","key":"10.1016\/j.jns.2026.125916_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(10)70224-6","article-title":"Energy metabolism in amyotrophic lateral sclerosis","volume":"10","author":"Dupuis","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.125916_bb0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fneur.2019.00284","article-title":"Lipid biomarkers for amyotrophic lateral sclerosis","volume":"10","author":"Gonzalez De Aguilar","year":"2019","journal-title":"Front. Neurol."},{"issue":"13","key":"10.1016\/j.jns.2026.125916_bb0020","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","article-title":"Dyslipidemia is a protective factor in amyotrophic lateral sclerosis","volume":"70","author":"Dupuis","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2026.125916_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/17482960802031092","article-title":"Are statin medications safe in patients with ALS?","volume":"9","author":"Zinman","year":"2008","journal-title":"Amyotroph. Lateral Scler."},{"issue":"1\u20132","key":"10.1016\/j.jns.2026.125916_bb0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jns.2008.06.022","article-title":"Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis","volume":"273","author":"Drory","year":"2008","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2026.125916_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70095","article-title":"Statin use and amyotrophic lateral sclerosis survival: a population-based cohort study","volume":"32","author":"Vaage","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2026.125916_bb0040","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/aje\/kwac054","article-title":"Statin medications and amyotrophic lateral sclerosis incidence and mortality","volume":"191","author":"Weisskopf","year":"2022","journal-title":"Am. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.jns.2026.125916_bb0045","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ana.26600","article-title":"Protective effects of lovastatin in a population-based ALS study and mouse model","volume":"93","author":"Kreple","year":"2023","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.125916_bb0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"issue":"10","key":"10.1016\/j.jns.2026.125916_bb0055","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1212\/WNL.0000000000201657","article-title":"Association between serum lipids and survival in patients with amyotrophic lateral sclerosis: a meta-analysis and population-based study","volume":"100","author":"Janse van Mantgem","year":"2023","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.jns.2026.125916_bb0060","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1212\/WNL.0b013e3181c1df1e","article-title":"Lower serum lipid levels are related to respiratory impairment in patients with ALS","volume":"73","author":"Chi\u00f2","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2026.125916_bb0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12944-020-01413-5","article-title":"A u-shaped association between the LDL-cholesterol to HDL-cholesterol ratio and all-cause mortality in elderly hypertensive patients: a prospective cohort study","volume":"19","author":"Yu","year":"2020","journal-title":"Lipids Health Dis."},{"issue":"5\u20136","key":"10.1016\/j.jns.2026.125916_bb0070","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/21678421.2025.2463943","article-title":"Amyotrophic lateral sclerosis and lovastatin: a promising treatment perspective","volume":"26","author":"Nadeem","year":"2025","journal-title":"Amyotroph Lateral Scler. Frontotemporal Degener."},{"issue":"3","key":"10.1016\/j.jns.2026.125916_bb0075","doi-asserted-by":"crossref","first-page":"632","DOI":"10.17305\/bb.2024.11218","article-title":"Therapeutic potential of simvastatin in ALS: enhanced axonal integrity and motor neuron survival through apoa4 and alb modulation","volume":"25","author":"Luo","year":"2025","journal-title":"Biomol. Biomed."},{"issue":"4","key":"10.1016\/j.jns.2026.125916_bb0080","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.25431","article-title":"Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis","volume":"85","author":"Bandres-Ciga","year":"2019","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2026.125916_bb0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/21678421.2023.2255622","article-title":"Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a mendelian randomization study","volume":"25","author":"Li","year":"2024","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"issue":"46","key":"10.1016\/j.jns.2026.125916_bb0090","doi-asserted-by":"crossref","first-page":"E1453","DOI":"10.1503\/cmaj.191721","article-title":"Canadian best practice recommendations for the management of amyotrophic lateral sclerosis","volume":"192","author":"Shoesmith","year":"2020","journal-title":"CMAJ"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X2600198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:21:57Z","timestamp":1778718117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X2600198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"alternative-id":["S0022510X2600198X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125916","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between statin use and survival in patients with ALS: A propensity score-matched analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125916"}}